Who
Jason Amello
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, TScan Therapeutics; Chief Financial Officer, Candel Therapeutics; Director, Acer Therapeutics; SVP, CFO & Treasurer, Akebia Therapeutics; Executive Vice President & CFO, Alaunos Therapeutics; CorpContrllr,ChiefAccntOfficer, Genzyme.
In numbers
- Trades disclosed
- 68
- Buys
- 4
- Sells
- 5
- Bought
- $91K
- Sold
- $657K
- Companies
- 6
- Companies where not an officer
- 1
- First trade
- 21 May 2009
- Last trade
- 20 Jan 2026
- Last filed
- 22 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jan 2026filed 22 Jan 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 3 Jan 2025filed 11 Feb 2025 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —270,000 at $0.00 | filing |
| 1 Feb 2024filed 2 Feb 2024 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 28 Nov 2023filed 30 Nov 2023 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code F | $18K20,153 at $0.90 | filing |
| 26 Nov 2023filed 28 Nov 2023 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code A | —125,717 at $0.00 | filing |
| 28 Apr 2023filed 2 May 2023 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 14 Mar 2023filed 16 Mar 2023 | Acer Therapeuticsoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 9 Dec 2022filed 12 Dec 2022 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,7632,468 at $1.93 | filing |
| 8 Dec 2022filed 12 Dec 2022 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,2393,100 at $1.69 | filing |
| 28 Nov 2022filed 30 Nov 2022 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code A | —90,877 at $0.00 | filing |
| 21 Sep 2022filed 23 Sep 2022 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 14 Jan 2022filed 19 Jan 2022 | Acer Therapeuticsoption or derivative | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 15 Jan 2021filed 20 Jan 2021 | Acer Therapeuticsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 28 Feb 2020filed 2 Mar 2020 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 28 Feb 2020filed 2 Mar 2020 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 28 Feb 2020filed 2 Mar 2020 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $61K6,976 at $8.70 | filing |
| 2 Jan 2020filed 3 Jan 2020 | Acer Therapeuticsoption or derivative | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 11 Apr 2019filed 12 Apr 2019 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code D | $101K13,148 at $7.70 | filing |
| 28 Feb 2019filed 5 Mar 2019 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
Comparing Keros Therapeutics (NASDAQ:KROS) and Akebia Therapeutics (NASDAQ:AKBA)AKBA · themarketsdaily.com · 24 Oct 2026Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026
0 headlines in the last 90 days name Jason Amello; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.